Gesynta Pharma AB
PrivateLast Round
Series B
Jul 22, 2025
Total Funding Raised
$43.4M
Company Overview
Gesynta Pharma AB is a clinical-stage pharmaceutical company that develops novel anti-inflammatory and pain-relieving drug candidates targeting the mPGES-1 enzyme for the treatment of chronic inflammatory diseases such as endometriosis.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Gesynta Pharma AB Comparables
Compare Gesynta Pharma AB with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Hope Medicine | 82% | |
| TiumBio Co., Ltd. | 77% | |
| FimmCyte | 77% | |
Gesynta Pharma AB Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jul 22, 2025 | ||||
| Series B | Jan 20, 2025 | ||||
| VC Round | Jul 7, 2020 | ||||
| VC Round | Apr 4, 2019 | ||||
| Series A | Feb 26, 2018 |
Gesynta Pharma AB Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Foreground Capital | Series B |
| Innovestor | Series B |
| Catalyze Capital | Series B |
| XGEN Venture | Series B |
| Innovestor Life Science | Series B |
| HealthCap | Series B |
| Industrifonden | Series B, VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 12, 2026
Phase 2 trial started for endometriosis drug vipoglanstat.
- Jul 22, 2025
Preparing Phase 2 trial for vipoglanstat, a novel endometriosis treatment.
Gesynta Pharma AB Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Gesynta Pharma AB's valuation, stock price, and market status.